INCAGN 1949Alternative Names: INCAGN 01949; INCAGN1949
Latest Information Update: 21 Feb 2017
At a glance
- Originator Agenus; Ludwig Institute for Cancer Research
- Developer Agenus; Incyte Corporation
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action OX40 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours